Immunic presents new vidofludimus calcium data at multiple sclerosis conference
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Thursday it presented three posters at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, North Carolina, including a late-breaking analysis of its lead drug candidate vidofludimus calcium in patients with progressive multiple sclerosis. The late-breaking poster introduced a novel unified endpoint called Confirmed Disability Change, designed to capture both disability worsening and improvement within a single statistical framework.
FTSE 100 Live: Global markets hit record highs, oil prices slide as Iran deal awaited
FTSE 100 up 13 points at 10,505 Asian and US tech stocks drive new global markets to all-time highs Energy prices and govt bonds ease on Iran optimism UK...
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named biopharmaceutical executive Erik Lundgren as its chief executive officer as the company advances its multiple sclerosis treatment candidate through late-stage development and prepares for potential commercialization. He succeeds Daniel Vitt, who will continue to oversee scientific strategy and portfolio advancement while remaining on the company's board of directors.
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout
Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed biopharmaceutical veteran Michael Bonney as chair of its board of directors. Bonney brings more than three decades of industry experience, including a background in multiple sclerosis and central nervous system markets.
Immunic advances Phase 3 MS program, eyes topline data by year-end
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Wednesday it remains on track to deliver top-line phase 3 data for its lead multiple sclerosis drug candidate, vidofludimus calcium, by the end of 2026, as the company strengthens its leadership team and bolsters its balance sheet with a recently completed $200 million private financing. Along with the release of its first quarter financial results, the biotechnology company said it continues to advance its twin phase 3 ENSURE-1 and ENSURE-2 trials evaluating vidofludimus calcium in relapsing multiple sclerosis (RMS).
Immunic: Saved By A 200 Million Private Placement
Immunic, Inc. (IMUX) is rated Hold due to high cash burn, heavy dilution, and reliance on a single near-term catalyst. Vidofludimus calcium (IMU-838) Phase 3 MS trial results, expected late 2026, are pivotal for IMUX's future revenue and valuation. Recent $187M private placement and $200M in warrants extend IMUX's cash runway to Phase 3 readout, and hopefully to the drugs rollout to the market, reducing near-term dilution risk.
Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named Michael A. Panzara as Chief Medical Officer, bringing aboard a veteran neurologist with more than 25 years of drug development experience as the biotechnology company braces for a critical clinical milestone in multiple sclerosis.
Immunic to implement 1-for-10 reverse stock split
Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced it will implement a 1-for-10 reverse stock split of its common shares, effective April 27, as part of efforts to meet contractual obligations tied to a recent securities agreement. The reverse split will take effect at 12:01 a.m.
Immunic appoints biopharmaceutical executive Jon Congleton to board
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has announced the appointment of veteran biopharmaceutical executive Jon Congleton to its board of directors, as the company advances its multiple sclerosis program through late-stage development. Congleton brings nearly four decades of experience in the biopharmaceutical industry, with a background spanning drug development, commercialization, and executive leadership, according to Immunic.
Immunic secures European patent for MS drug candidate vidofludimus calcium
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Tuesday the European Patent Office has granted a key patent covering dosing regimens for its experimental multiple sclerosis treatment vidofludimus calcium, extending potential market protection for the drug candidate in Europe to 2038. The patent, EP3713554, protects label-relevant dosing regimens of vidofludimus calcium and broadly covers the compound and its salt, solvate and free acid forms when used according to the approved label, the company said.
Immunic to present at healthcare investor conferences in March
Immunic Inc (NASDAQ:IMUX), a late-stage biotechnology company developing oral treatments for neurological and gastrointestinal diseases, will participate in two investor conferences this month. Chief executive Daniel Vitt and president Jason Tardio will take part in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami on 11 March, with one-on-one investor meetings also scheduled across the event, which runs from 8 to 11 March.
Immunic secures $400M to support late-stage MS trials - ICYMI
Immunic Inc (NASDAQ:IMUX) earlier this week outlined how a newly secured up to $400 million private placement is set to support completion of late-stage trials and prepare the company for a potential commercial launch of vidofludimus calcium in multiple sclerosis. Speaking to Proactive, CEO Dr Daniel Vitt described the financing as “a transformative transaction for the company,” noting that $200 million has already been received, with the remainder available in a second tranche.
